Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Grail announced that results from the registrational PATHFINDER 2 study of its Galleri multi-cancer early detection test showed that adding the test to standard-of-care screening resulted in ...

Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009. Loss of patent-protected exclusivity for several ...

Pfizer's built from many pieces that are moving in opposite directions. To make sure this stock isn't a yield trap destined to slash its dividend payout in the near term, let's weigh the good news ...

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an allegation that clinical testing related to the development of the ...

The Justice Department changed its policy on foreign corruption cases, which might have put an end to investigations into the pharmaceutical company.

Dr. Philip Dormitzer, former global head of vaccine research and development at Pfizer, has been subpoenaed by the House Judiciary Committee as it investigates Pfizer’s alleged delay in the ...

(RTTNews) - XtalPi (2228.HK) announced an expanded research collaboration with Pfizer (PFE) to develop a next-generation molecular modeling platform for drug discovery. The initiative aims to ...